In addition, the dataset used in this study is rather old, and few internal medications that improve prognosis including angiotensin receptor neprilysin inhibitor and sodium-glucose cotransporter 2 inhibitors, which are currently the mainstay of heart failure medications [35,36,37], were used. This evidence concerns the gene SLC5A2 and heart failure.